Literature DB >> 22493360

EPLIN-α expression in human oesophageal cancer and its impact on cellular aggressiveness and clinical outcome.

Yinan Liu1, Andrew J Sanders, Lijian Zhang, Wen G Jiang.   

Abstract

BACKGROUND: Epithelial protein lost in neoplasm-α (EPLIN-α) is a cytoskeletal protein whose expression is often lost or is aberrant in cancerous cells and tissues and whose loss is believed to be involved in aggressive phenotype. Our current study examined this molecule in human oesophageal tissues and investigated the cellular impact of EPLIN-α on oesophageal cancer cells.
MATERIALS AND METHODS: Expression of the EPLIN-α transcript in human oesophageal tissues (tumour, paratumour and normal) was determined using the Quantitative Polymerase Chain Reaction (Q-PCR) method. In vitro models, including invasion, cellular migration (Electrical Cell substrate Impedance Sensing based method), cell growth and matrix adhesion assays were employed in order to assess the biological influence of EPLIN-α expression on KYSE150 oesophageal cancer cells.
RESULTS: EPLIN-α expression was lower in tumour tissues compared to normal tissue. Grade 3-5 tumours had slightly lower levels of EPLIN-α compared with those of grade 2. Patients who died of oesophageal cancer had significantly lower levels of EPLIN-α compared to those who remained disease-free (p=0.022). Lower levels of EPLIN-α transcript were seen in advanced oesophageal cancer, including TNM stages 2 to 4. Reduced EPLIN-α expression was associated with lymphatic metastasis and local advanced T-stage cancer, including T2-T4. Forced expression of EPLIN-α in oesophageal cancer cells rendered cells less invasive and reduced their cell growth rate in vitro.
CONCLUSION: Our study suggests that EPLIN-α is expressed at lower levels in oesophageal cancer tissues. This down-regulation has a prognostic value. Together with the findings that EPLIN-α inhibits cellular growth and invasion, we conclude that EPLIN-α is a tumour suppressor of oesophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493360

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition.

Authors:  Shumin Zhang; Xu Wang; Shareen Iqbal; Yanru Wang; Adeboye O Osunkoya; Zhengjia Chen; Zhuo Chen; Dong M Shin; Hongwei Yuan; Yongqiang A Wang; Haiyen E Zhau; Leland W K Chung; Chad Ritenour; Omer Kucuk; Daqing Wu
Journal:  J Biol Chem       Date:  2012-11-27       Impact factor: 5.157

Review 2.  EPLIN: a fundamental actin regulator in cancer metastasis?

Authors:  Ross J Collins; Wen G Jiang; Rachel Hargest; Malcolm D Mason; Andrew J Sanders
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

3.  LUZP1 and the tumor suppressor EPLIN modulate actin stability to restrict primary cilia formation.

Authors:  João Gonçalves; Amit Sharma; Étienne Coyaud; Estelle M N Laurent; Brian Raught; Laurence Pelletier
Journal:  J Cell Biol       Date:  2020-07-06       Impact factor: 10.539

4.  EPLIN Expression in Gastric Cancer and Impact on Prognosis and Chemoresistance.

Authors:  Wenjing Gong; Jianyuan Zeng; Jiafu Ji; Yongning Jia; Shuqin Jia; Andrew J Sanders; Wen G Jiang
Journal:  Biomolecules       Date:  2021-04-08

5.  LUZP1 Controls Cell Division, Migration and Invasion Through Regulation of the Actin Cytoskeleton.

Authors:  Laura Bozal-Basterra; María Gonzalez-Santamarta; Veronica Muratore; Natalia Martín-Martín; Amaia Ercilla; Jose A Rodríguez; Arkaitz Carracedo; James D Sutherland; Rosa Barrio
Journal:  Front Cell Dev Biol       Date:  2021-04-01

Review 6.  Epithelial protein lost in neoplasm (EPLIN): Beyond a tumor suppressor.

Authors:  Daqing Wu
Journal:  Genes Dis       Date:  2017-04-01

7.  Lima1 mediates the pluripotency control of membrane dynamics and cellular metabolism.

Authors:  Binyamin Duethorn; Fabian Groll; Bettina Rieger; Hannes C A Drexler; Heike Brinkmann; Ludmila Kremer; Martin Stehling; Marie-Theres Borowski; Karina Mildner; Dagmar Zeuschner; Magdalena Zernicka-Goetz; Marc P Stemmler; Karin B Busch; Juan M Vaquerizas; Ivan Bedzhov
Journal:  Nat Commun       Date:  2022-02-01       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.